Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas

<b>Background:</b> as the most common malignancy of the central nervous system, low-grade glioma (LGG) patients suffered a poor prognosis. Tumor microenvironment, especially immune components, plays an important role in the progression of tumors. Thus, it is critical to explore the key i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ming Wang, Jiaoying Jia, Yan Cui, Yong Peng, Yugang Jiang
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	low-grade glioma TME immune cell infiltration immunotherapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/0c2d481f95d648779df4b4da2eabcccb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0c2d481f95d648779df4b4da2eabcccb
record_format	dspace
spelling	oai:doaj.org-article:0c2d481f95d648779df4b4da2eabcccb2021-11-25T16:59:08ZMolecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas10.3390/brainsci111115292076-3425https://doaj.org/article/0c2d481f95d648779df4b4da2eabcccb2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1529https://doaj.org/toc/2076-3425<b>Background:</b> as the most common malignancy of the central nervous system, low-grade glioma (LGG) patients suffered a poor prognosis. Tumor microenvironment, especially immune components, plays an important role in the progression of tumors. Thus, it is critical to explore the key immune-related genes, a comprehensive understanding of the TME in LGG helps us find novel cancer biomarkers and therapeutic targets. <b>Methods:</b> the GPSM3 expression level and the correlations between clinical characteristics and GPSM3 levels were analyzed with the data from CGGA and TCGA dataset. Univariate and multivariate cox regression model were built to predict the prognosis of LGG patients with multiple factors. Then the correlation between GPSM3 with immune cell infiltration was explored by ESTIMATE, CIBERSORT and TIMER2.0. At last, the correlation analyzed between GPSM3 expression and immune checkpoint related genes were also analyzed. <b>Results:</b> GPSM3 expression was overexpressed in LGG and negatively correlated to the GPSM3 DNA methylation. Univariate and multivariate Cox analysis demonstrated that GPSM3 expression was an independent prognostic factor in LGG patients. Functional characterization of GPSM3 revealed that it was associated with many immune processes to tumor cells. GPSM3 expression was positive related to the immune score, Stromal scores and ESTIMATE scores, but negative related to the Tumor purity. Immune features in the TME of GPSM3-high LGG group is characterized by a higher infiltrating of regulatory T cells, neutrophils, macrophages M2, and a lower proportion of monocytes than to the GPSM3-low group. Furthermore, GPSM3 expression exhibited significant correlations with the immune checkpoint-related genes, especially PD-1, PD-L1, PD-L2, CTLA4 and TIM3. <b>Conclusions:</b> these findings proved that GPSM3 could serve as a prognostic biomarker and potential immunotherapy target for LGG.Ming WangJiaoying JiaYan CuiYong PengYugang JiangMDPI AGarticlelow-grade gliomaTMEimmune cell infiltrationimmunotherapyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1529, p 1529 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	low-grade glioma TME immune cell infiltration immunotherapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	low-grade glioma TME immune cell infiltration immunotherapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Ming Wang Jiaoying Jia Yan Cui Yong Peng Yugang Jiang Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas
description	<b>Background:</b> as the most common malignancy of the central nervous system, low-grade glioma (LGG) patients suffered a poor prognosis. Tumor microenvironment, especially immune components, plays an important role in the progression of tumors. Thus, it is critical to explore the key immune-related genes, a comprehensive understanding of the TME in LGG helps us find novel cancer biomarkers and therapeutic targets. <b>Methods:</b> the GPSM3 expression level and the correlations between clinical characteristics and GPSM3 levels were analyzed with the data from CGGA and TCGA dataset. Univariate and multivariate cox regression model were built to predict the prognosis of LGG patients with multiple factors. Then the correlation between GPSM3 with immune cell infiltration was explored by ESTIMATE, CIBERSORT and TIMER2.0. At last, the correlation analyzed between GPSM3 expression and immune checkpoint related genes were also analyzed. <b>Results:</b> GPSM3 expression was overexpressed in LGG and negatively correlated to the GPSM3 DNA methylation. Univariate and multivariate Cox analysis demonstrated that GPSM3 expression was an independent prognostic factor in LGG patients. Functional characterization of GPSM3 revealed that it was associated with many immune processes to tumor cells. GPSM3 expression was positive related to the immune score, Stromal scores and ESTIMATE scores, but negative related to the Tumor purity. Immune features in the TME of GPSM3-high LGG group is characterized by a higher infiltrating of regulatory T cells, neutrophils, macrophages M2, and a lower proportion of monocytes than to the GPSM3-low group. Furthermore, GPSM3 expression exhibited significant correlations with the immune checkpoint-related genes, especially PD-1, PD-L1, PD-L2, CTLA4 and TIM3. <b>Conclusions:</b> these findings proved that GPSM3 could serve as a prognostic biomarker and potential immunotherapy target for LGG.
format	article
author	Ming Wang Jiaoying Jia Yan Cui Yong Peng Yugang Jiang
author_facet	Ming Wang Jiaoying Jia Yan Cui Yong Peng Yugang Jiang
author_sort	Ming Wang
title	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas
title_short	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas
title_full	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas
title_fullStr	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas
title_full_unstemmed	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas
title_sort	molecular and clinical characterization of a novel prognostic and immunologic biomarker gpsm3 in low-grade gliomas
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0c2d481f95d648779df4b4da2eabcccb
work_keys_str_mv	AT mingwang molecularandclinicalcharacterizationofanovelprognosticandimmunologicbiomarkergpsm3inlowgradegliomas AT jiaoyingjia molecularandclinicalcharacterizationofanovelprognosticandimmunologicbiomarkergpsm3inlowgradegliomas AT yancui molecularandclinicalcharacterizationofanovelprognosticandimmunologicbiomarkergpsm3inlowgradegliomas AT yongpeng molecularandclinicalcharacterizationofanovelprognosticandimmunologicbiomarkergpsm3inlowgradegliomas AT yugangjiang molecularandclinicalcharacterizationofanovelprognosticandimmunologicbiomarkergpsm3inlowgradegliomas
_version_	1718412818110218240

Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas

Ejemplares similares